ARDX logo

ARDX Ardelyx, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$2.99
-0.07 (-2.29%)

Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phas…

Market Cap: $751.60Mwww.ardelyx.com

Price

No data yet.

Social Signal Score

55
5d
70
1 mentions
—
30d
54
9 mentions
—
60d
49
17 mentions
—
90d
47
22 mentions
—
news: 22

Analyst Ratings

16 analysts
Buyconsensus
Strong Buy 0Buy 16Hold 0Sell 0Strong Sell 0
Avg price target$13+334.8%
Low $13Median $13High $13
Current Consensus

Revenue

$127.66M
$0.00$42.55M$85.10M$127.66M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.24
$-0.27–$-0.21
7 analysts
FY2026
$-0.19
$-0.22–$-0.17
8 analysts
FY2027
$0.19
$0.04–$0.60
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Michael G. Raab
Sector
Healthcare
Industry
Biotechnology
Employees
489
Beta
0.68
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-0.06
www.ardelyx.com